The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse

ConclusionThe acute treatment of migraine will certainly improve with the advent of two novel classes of drugs, i.e., the 5-HT1F receptor agonists (lasmiditan) and the small molecule CGRP receptor antagonists (gepants). Data on the effects of 5-HT1F receptor agonism in relation to MOH, as well as the effects of chronic CGRP receptor blockade, are awaited with interest.

http://link.springer.com/10.1186/s10194-019-1007-y

Source: The Journal of Headache and Pain - May 15, 2019 Category: Neurology Source Type: research